Jacques Grosset

Research output

Research output per year 1956 1978 1982 1983 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2005 2009 2011 2013 2015 2020

• 365 Article
• 23 Review article
• 19 Letter
• 10 Editorial
• 17 More
  • 8 Comment/debate
  • 4 Chapter
  • 4 Short survey
  • 1 Book

Research output per year

Research output per year

Search results

• 2020

  Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial

  study team, Apr 18 2020, In: The Lancet. 395, 10232, p. 1259-1267 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Buruli Ulcer 100%
  • Clarithromycin 75%
  • Streptomycin 74%
  • Rifampin 67%
  • Therapeutics 10%
• 2019

  High-dose rifamycins enable shorter oral treatment in a murine model of mycobacterium ulcerans disease

  Omansen, T. F., Almeida, D., Converse, P., Li, S. Y., Lee, J., Stienstra, Y., van der Werf, T., Grosset, J. H. & Nuermberger, E. L., Feb 2019, In: Antimicrobial agents and chemotherapy. 63, 2, e01478-18.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Rifamycins 100%
  • Mycobacterium ulcerans 94%
  • rifapentine 81%
  • Rifampin 61%
  • Buruli Ulcer 61%
  9 Scopus citations

• Oxazolidinones can replace clarithromycin in combination with rifampin in a mouse model of Buruli ulcer

  Almeida, D. V., Omansen, T. F., Li, S. Y., Lee, J., Grosset, J. H., Converse, P. J. & Nuermberger, E. L., Mar 2019, In: Antimicrobial agents and chemotherapy. 63, 3, e02171-18.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Buruli Ulcer 100%
  • Oxazolidinones 97%
  • Clarithromycin 75%
  • PNU-100480 72%
  • Rifampin 67%
  2 Scopus citations

• Treatment-shortening effect of a novel regimen combining clofazimine and high-dose rifapentine in pathologically distinct mouse models of tuberculosis

  Saini, V., Ammerman, N. C., Chang, Y. S., Tasneen, R., Chaisson, R. E., Jain, S., Nuermberger, E. & Grosset, J. H., Jun 2019, In: Antimicrobial agents and chemotherapy. 63, 6, e00388-19.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • rifapentine 100%
  • Clofazimine 89%
  • Tuberculosis 48%
  • Rifampin 20%
  • Duration of Therapy 18%
  5 Scopus citations
• 2018

  An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++

  Mieras, L. F., Taal, A. T., Van Brakel, W. H., Cambau, E., Saunderson, P. R., Smith, W. C. S., Prakoeswa, C. R. S., Astari, L., Scollard, D. M., Do Nascimento, D. C., Grosset, J., Kar, H. K., Izumi, S., Gillini, L., Virmond, M. C. L. & Sturkenboom, M. G. G., Oct 5 2018, In: BMC infectious diseases. 18, 1, 506.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Post-Exposure Prophylaxis 100%
  • Leprosy 79%
  • Chemoprevention 76%
  • Rifampin 26%
  • Moxifloxacin 24%

• C-reactive protein as a screening test for HIVassociated pulmonary tuberculosis prior to antiretroviral therapy in South Africa

  Shapiro, A. E., Hong, T., Govere, S., Thulare, H., Moosa, M. Y., Dorasamy, A., Wallish, C. L., Celum, C. L., Grosset, J. & Drain, P. K., 2018, In: AIDS. 32, 13, p. 1811-1820 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • South Africa 100%
  • Pulmonary Tuberculosis 99%
  • C-Reactive Protein 83%
  • Tuberculosis 78%
  • HIV 26%

• Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis

  Ammerman, N. C., Swanson, R. V., Bautista, E. M., Almeida, D. V., Saini, V., Omansen, T. F., Guo, H., Chang, Y. S., Li, S. Y., Tapley, A., Tasneen, R., Tyagi, S., Betoudji, F., Moodley, C., Ngcobo, B., Pillay, L., Bester, L. A., Singh, S. D., Chaisson, R. E., Nuermberger, E., & 1 othersGrosset, J. H., Jul 2018, In: Antimicrobial agents and chemotherapy. 62, 7, e00636-18.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Clofazimine 100%
  • Tuberculosis 54%
  • Pharmaceutical Preparations 15%
  • Drug Evaluation 11%
  • Multidrug-Resistant Tuberculosis 11%
  12 Scopus citations

• Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

  Converse, P. J., Almeida, D. V., Tasneen, R., Saini, V., Tyagi, S., Ammerman, N. C., Li, S. Y., Anders, N. M., Rudek, M. A., Grosset, J. H. & Nuermberger, E. L., Aug 2018, In: PLoS neglected tropical diseases. 12, 8, e0006728.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Rifamycins 100%
  • Mycobacterium ulcerans 94%
  • Buruli Ulcer 92%
  • Clofazimine 88%
  • Rifampin 61%
  15 Scopus citations

• Tuberculosis in France before, during, and after World War II

  Grosset, J. & Trébucq, A., 2018, In: Progress in Respiratory Research. 43, p. 116-123 8 p.

  Research output: Contribution to journal › Review article › peer-review

  • World War II 100%
  • France 69%
  • Tuberculosis 60%
  • World War I 46%
  • Concentration Camps 26%
• 2017

  Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo

  Ammerman, N. C., Swanson, R. V., Tapley, A., Moodley, C., Ngcobo, B., Adamson, J., Dorasamy, A., Moodley, S., Mgaga, Z., Bester, L. A., Singh, S. D., Almeida, D. V. & Grosset, J. H., Feb 2017, In: Journal of Antimicrobial Chemotherapy. 72, 2, p. 455-461 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Clofazimine 100%
  • Mycobacterium tuberculosis 64%
  • In Vitro Techniques 29%
  • Pharmaceutical Preparations 9%
  • Leprosy 8%
  21 Scopus citations

• Conclusions and future directions

  Chaisson, R. E. & Grosset, J., Mar 30 2017, Handbook of Tuberculosis. Springer International Publishing, p. 219-221 3 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

• Emerging therapies

  Lamichhane, G. & Grosset, J., Mar 30 2017, Handbook of Tuberculosis. Springer International Publishing, p. 191-218 28 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

• Handbook of Tuberculosis

  Grosset, J. & Chaisson, R. E., Mar 30 2017, Springer International Publishing. 221 p.

  Research output: Book/Report › Book

  • Tuberculosis 100%
  • Infectious Diseases 33%
  • Text 27%
  • Lung 19%
  • Healthcare 18%
• 2016

  Clofazimine contributes sustained antimicrobial activity after treatment cessation in a mouse model of tuberculosis chemotherapy

  Swanson, R. V., Ammerman, N. C., Ngcobo, B., Adamson, J., Moodley, C., Dorasamy, A., Moodley, S., Mgaga, Z., Bester, L. A., Singh, S. D., Almeida, D. V. & Grosset, J. H., May 2016, In: Antimicrobial agents and chemotherapy. 60, 5, p. 2864-2869 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Clofazimine 100%
  • Withholding Treatment 80%
  • Tuberculosis 54%
  • Drug Therapy 39%
  • Isoniazid 13%
  15 Scopus citations

• Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance

  Desjardins, C. A., Cohen, K. A., Munsamy, V., Abeel, T., Maharaj, K., Walker, B. J., Shea, T. P., Almeida, D. V., Manson, A. L., Salazar, A., Padayatchi, N., O'Donnell, M. R., Mlisana, K. P., Wortman, J., Birren, B. W., Grosset, J., Earl, A. M. & Pym, A. S., May 1 2016, In: Nature genetics. 48, 5, p. 544-551 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cycloserine 100%
  • Mycobacterium tuberculosis 66%
  • Drug Resistance 31%
  • Alanine Dehydrogenase 30%
  • Pharmaceutical Preparations 28%
  88 Scopus citations

• Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis

  Almeida, D., Ioerger, T., Tyagi, S., Li, S. Y., Mdluli, K., Andries, K., Grosset, J., Sacchettini, J. & Nuermberger, E., Aug 2016, In: Antimicrobial agents and chemotherapy. 60, 8, p. 4590-4599 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • bedaquiline 100%
  • Clofazimine 91%
  • Mycobacterium tuberculosis 59%
  • Mutation 34%
  • Multidrug-Resistant Tuberculosis 16%
  75 Scopus citations
• 2015

  A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline

  Grosset, J. & Vernon, A., Apr 15 2015, In: American journal of respiratory and critical care medicine. 191, 8, p. 871-873 3 p.

  Research output: Contribution to journal › Editorial › peer-review
  4 Scopus citations

• Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations

  Andréjak, C., Almeida, D. V., Tyagi, S., Converse, P. J., Ammerman, N. C. & Grosset, J. H., Apr 1 2015, In: Antimicrobial agents and chemotherapy. 59, 4, p. 2129-2135 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Mycobacterium avium 100%
  • Mycobacterium avium Complex 97%
  • Drug Combinations 76%
  • Clarithromycin 75%
  • Moxifloxacin 55%
  14 Scopus citations

• Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

  Tyagi, S., Ammerman, N. C., Li, S. Y., Adamson, J., Converse, P. J., Swanson, R. V., Almeida, D. V. & Grosset, J. H., Jan 20 2015, In: Proceedings of the National Academy of Sciences of the United States of America. 112, 3, p. 869-874 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Clofazimine 100%
  • Tuberculosis 54%
  • Drug Therapy 39%
  • Isoniazid 30%
  • Rifampin 28%
  88 Scopus citations

• Efficacy of rifampin plus clofazimine in a murine model of Mycobacterium ulcerans disease

  Converse, P. J., Tyagi, S., Xing, Y., Li, S. Y., Kishi, Y., Adamson, J., Nuermberger, E. L. & Grosset, J. H., Jun 4 2015, In: PLoS neglected tropical diseases. 9, 6, e0003823.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mycobacterium ulcerans 100%
  • Clofazimine 93%
  • Rifampin 65%
  • relapse 49%
  • contagious disease 40%
  19 Scopus citations

• Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal

  Cohen, K. A., Abeel, T., Manson McGuire, A., Desjardins, C. A., Munsamy, V., Shea, T. P., Walker, B. J., Bantubani, N., Almeida, D. V., Alvarado, L., Chapman, S. B., Mvelase, N. R., Duffy, E. Y., Fitzgerald, M. G., Govender, P., Gujja, S., Hamilton, S., Howarth, C., Larimer, J. D., Maharaj, K., & 13 othersPearson, M. D., Priest, M. E., Zeng, Q., Padayatchi, N., Grosset, J., Young, S. K., Wortman, J., Mlisana, K. P., O'Donnell, M. R., Birren, B. W., Bishai, W. R., Pym, A. S. & Earl, A. M., Sep 2015, In: PLoS medicine. 12, 9, e1001880.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Extensively Drug-Resistant Tuberculosis 100%
  • Whole Genome Sequencing 78%
  • Mycobacterium tuberculosis 65%
  • Rifampin 53%
  • Disease Outbreaks 52%
  142 Scopus citations

• Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa

  Cohen, K. A., Abeel, T., McGuire, A. M., Desjardins, C. A., Munsamy, V., Shea, T. P., Walker, B. J., Bantubani, N., Almeida, D. V., Alvarado, L., Chapman, S., Mvelase, N. R., Duffy, E. Y., Fitzgerald, M. G., Govender, P., Gujja, S., Hamilton, S., Howarth, C., Larimer, J. D., Maharaj, K., & 13 othersPearson, M. D., Priest, M. E., Zeng, Q., Padayatchi, N., Grosset, J., Young, S. K., Wortman, J., Mlisana, K. P., O'Donnell, M. R., Birren, B. W., Bishai, W. R., Pym, A. S. & Earl, A. M., 2015, (Accepted/In press) In: International Journal of Mycobacteriology.

  Research output: Contribution to journal › Article › peer-review

  • Extensively Drug-Resistant Tuberculosis 100%
  • Whole Genome Sequencing 78%
  • South Africa 70%
  • Mycobacterium tuberculosis 65%
  • Drug Resistance 61%

• Flu-like and Other Systemic Drug Reactions among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study

  Sterling, T. R., Moro, R. N., Borisov, A. S., Phillips, E., Shepherd, G., Adkinson, N. F., Weis, S., Ho, C., Villarino, M. E., Adkinson, N. F., Grosset, J., Hackman, J., Hamilton, R. G., Villarino, M. E., Shang, N., Gordin, F., Khan, A., Hamilton, C. D., Menzies, D., Kerrigan, A., & 11 othersHorsburgh, C. R., Chaisson, R. E., McSherry, G., Arevalo, B., Vernon, A., Kleinbaum, D. G., Heilig, C., Fryer, K., Sanchez, I., Lam, S. K. & Scott, N., Aug 15 2015, In: Clinical Infectious Diseases. 61, 4, p. 527-535 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • rifapentine 100%
  • Latent Tuberculosis 77%
  • Isoniazid 67%
  • Tuberculosis 48%
  • Odds Ratio 38%
  46 Scopus citations

• Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis

  Swanson, R. V., Adamson, J., Moodley, C., Ngcobo, B., Ammerman, N. C., Dorasamy, A., Moodley, S., Mgaga, Z., Tapley, A., Bester, L. A., Singh, S., Grosset, J. H. & Almeida, D. V., Jun 1 2015, In: Antimicrobial agents and chemotherapy. 59, 6, p. 3042-3051 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Clofazimine 100%
  • Tuberculosis 54%
  • Pharmacokinetics 50%
  • Pharmaceutical Preparations 17%
  • Mycobacterium tuberculosis 8%
  57 Scopus citations

• Targeting DnaN for tuberculosis therapy using novel griselimycins

  Kling, A., Lukat, P., Almeida, D. V., Bauer, A., Fontaine, E., Sordello, S., Zaburannyi, N., Herrmann, J., Wenzel, S. C., König, C., Ammerman, N. C., Barrio, M. B., Borchers, K., Bordon-Pallier, F., Brönstrup, M., Courtemanche, G., Gerlitz, M., Geslin, M., Hammann, P., Heinz, D. W., & 12 othersHoffmann, H., Klieber, S., Kohlmann, M., Kurz, M., Lair, C., Matter, H., Nuermberger, E., Tyagi, S., Fraisse, L., Grosset, J. H., Lagrange, S. & Müller, R., Jun 5 2015, In: Science. 348, 6239, p. 1106-1112 7 p.

  Research output: Contribution to journal › Article › peer-review

  • griselimycin 100%
  • Tuberculosis 34%
  • Streptomyces 34%
  • Mycobacterium tuberculosis 27%
  • Multidrug-Resistant Tuberculosis 17%
  170 Scopus citations
• 2014

  Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease

  Converse, P. J., Xing, Y., Kim, K. H., Tyagi, S., Li, S. Y., Almeida, D. V., Nuermberger, E. L., Grosset, J. H. & Kishi, Y., Jan 2014, In: PLoS neglected tropical diseases. 8, 1, p. 52 1 p., e2618.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • mycolactone 100%
  • Mycobacterium ulcerans 88%
  • Thin Layer Chromatography 65%
  • Rifampin 58%
  • Anti-Bacterial Agents 36%
  23 Scopus citations
• 2013

  Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice

  Grosset, J. H., Tyagi, S., Almeida, D. V., Converse, P. J., Li, S. Y., Ammerman, N. C., Bishai, W. R., Enarson, D. & Trébucq, A., Sep 1 2013, In: American journal of respiratory and critical care medicine. 188, 5, p. 608-612 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Clofazimine 100%
  • Tuberculosis 54%
  • Multidrug-Resistant Tuberculosis 20%
  • Withholding Treatment 20%
  • Recurrence 14%
  85 Scopus citations

• Bactericidal Activity Does Not Predict Sterilizing Activity: The Case of Rifapentine in the Murine Model of Mycobacterium ulcerans Disease

  Almeida, D. V., Converse, P. J., Li, S. Y., Tyagi, S., Nuermberger, E. L. & Grosset, J. H., Feb 2013, In: PLoS neglected tropical diseases. 7, 2, e2085.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • rifapentine 100%
  • Mycobacterium ulcerans 95%
  • Streptomycin 69%
  • Rifampin 47%
  • drug 40%
  15 Scopus citations

• Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis

  Ahmad, Z., Tyagi, S., Minkowski, A., Peloquin, C. A., Grosset, J. H. & Nuermberger, E. L., Jul 1 2013, In: American journal of respiratory and critical care medicine. 188, 1, p. 97-102 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pyrazinamide 100%
  • Moxifloxacin 97%
  • Tuberculosis 61%
  • Fluoroquinolones 55%
  • Ethionamide 39%
  42 Scopus citations

• Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)

  Grosset, J. H. & Ammerman, N. C., Jul 2013, In: Expert Review of Anti-Infective Therapy. 11, 7, p. 649-651 3 p.

  Research output: Contribution to journal › Review article › peer-review

  • bedaquiline 100%
  • Pharmaceutical Preparations 25%
  • Rifampin 12%
  • Pulmonary Tuberculosis 12%
  • Sputum 12%
  3 Scopus citations

• Improving existing tools for Mycobacterium xenopi treatment: Assessment of drug combinations and characterization of mouse models of infection and chemotherapy

  Andréjak, C., Almeida, D. V., Tyagi, S., Converse, P., Ammerman, N. & Grosset, J. H., Mar 2013, In: Journal of Antimicrobial Chemotherapy. 68, 3, p. 659-665 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mycobacterium xenopi 100%
  • Drug Combinations 59%
  • Moxifloxacin 41%
  • Drug Therapy 33%
  • Clarithromycin 30%
  15 Scopus citations

• Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease

  Sarfo, F. S., Converse, P. J., Almeida, D. V., Zhang, J., Robinson, C., Wansbrough-Jones, M. & Grosset, J. H., 2013, In: PLoS neglected tropical diseases. 7, 3, e2101.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mycobacterium ulcerans 100%
  • mycolactone 62%
  • Anti-Bacterial Agents 40%
  • Buruli Ulcer 32%
  • Bacillus 27%
  26 Scopus citations

• Rapid, Serial, Non-invasive Assessment of Drug Efficacy in Mice with Autoluminescent Mycobacterium ulcerans Infection

  Zhang, T., Li, S. Y., Converse, P. J., Grosset, J. H. & Nuermberger, E. L., 2013, In: PLoS neglected tropical diseases. 7, 12, e2598.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mycobacterium ulcerans 100%
  • Buruli Ulcer 97%
  • drug 42%
  • Pharmaceutical Preparations 25%
  • Drug Evaluation 25%
  21 Scopus citations

• Reply to contradictory results with high-dosage rifamycin in mice and humans

  Nuermberger, E. L., Rosenthal, I. M., Tasneen, R., Peloquin, C. A., Mdluli, K. E., Karakousis, P. C. & Grosset, J. H., Feb 2013, In: Antimicrobial agents and chemotherapy. 57, 2, p. 1104-1105 2 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  3 Scopus citations

• Streptomycin

  Grosset, J. H. & Singer, T., Feb 27 2013, Brenner's Encyclopedia of Genetics: Second Edition. Elsevier Inc., p. 568-569 2 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Streptomycin 100%
  • streptomycin 78%
  • penicillins 77%
  • Penicillins 75%
  • antibiotics 56%
• 2012

  Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis

  Ahmad, Z., Tyagi, S., Minkowski, A., Almeida, D., Nuermberger, E. L., Peck, K. M., Welch, J. T., Baughn, A. S., Jacobs, W. R. & Grosset, J. H., Nov 2012, In: Indian Journal of Medical Research. 136, 5, p. 808-814 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Pyrazinamide 100%
  • Mycobacterium bovis 80%
  • Mycobacterium tuberculosis 72%
  • Tuberculosis 20%
  • Microbial Sensitivity Tests 19%
  13 Scopus citations

• Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis

  Rosenthal, I. M., Tasneen, R., Peloquin, C. A., Zhang, M., Almeida, D., Mdluli, K. E., Karakousis, P. C., Grosset, J. H. & Nuermberger, E. L., Aug 2012, In: Antimicrobial agents and chemotherapy. 56, 8, p. 4331-4340 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • rifapentine 100%
  • Rifampin 62%
  • Tuberculosis 48%
  • Pyrazinamide 31%
  • Isoniazid 27%
  98 Scopus citations

• Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide

  Grosset, J., Almeida, D., Converse, P. J., Tyagi, S., Li, S. Y., Ammerman, N. C., Pym, A. S., Wallengren, K., Hafner, R., Lalloo, U., Swindells, S. & Bishai, W. R., Sep 11 2012, In: Proceedings of the National Academy of Sciences of the United States of America. 109, 37, p. 15001-15005 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pyrazinamide 100%
  • Isoniazid 85%
  • Tuberculosis 61%
  • Moxifloxacin 10%
  • Ethambutol 10%
  30 Scopus citations

• New drugs for the treatment of tuberculosis: Hope and reality

  Grosset, J. H., Singer, T. G. & Bishai, W. R., Aug 1 2012, In: International Journal of Tuberculosis and Lung Disease. 16, 8, p. 1005-1014 10 p.

  Research output: Contribution to journal › Review article › peer-review

  • Tuberculosis 100%
  • Ethambutol 93%
  • Pharmaceutical Preparations 50%
  • posizolid 50%
  • PNU-100480 48%
  96 Scopus citations

• Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs

  Dutta, N. K., Illei, P. B., Peloquin, C. A., Pinn, M. L., Mdluli, K. E., Nuermberger, E. L., Grosset, J. H. & Karakousis, P. C., Jul 2012, In: Antimicrobial agents and chemotherapy. 56, 7, p. 3726-3731 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • rifapentine 100%
  • Rifampin 62%
  • Guinea Pigs 52%
  • Tuberculosis 48%
  • Pyrazinamide 26%
  31 Scopus citations

• The added effect of thioridazine in the treatment of drug-resistant tuberculosis: Reply

  Grosset, J. H. & Bishai, W. R., Dec 1 2012, In: International Journal of Tuberculosis and Lung Disease. 16, 12, p. 1708-1709 2 p.

  Research output: Contribution to journal › Letter › peer-review

• The chemotherapy of leprosy: an interpretive history.

  Gelber, R. H. & Grosset, J., Sep 1 2012, In: Leprosy review. 83, 3, p. 221-240 20 p.

  Research output: Contribution to journal › Editorial › peer-review
  16 Scopus citations
• 2011

  Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice

  Almeida, D., Converse, P. J., Ahmad, Z., Dooley, K. E., Nuermberger, E. L. & Grosset, J. H., 2011, In: PLoS neglected tropical diseases. 5, 1, e933.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • rifapentine 100%
  • Mycobacterium ulcerans 95%
  • Clarithromycin 71%
  • Rifampin 62%
  • Streptomycin 32%
  32 Scopus citations

• Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis

  Ahmad, Z., Minkowski, A., Peloquin, C. A., Williams, K. N., Mdluli, K. E., Grosset, J. H. & Nuermberger, E. L., Apr 2011, In: Antimicrobial agents and chemotherapy. 55, 4, p. 1781-1783 3 p.

  Research output: Contribution to journal › Article › peer-review

  • 7-(7-amino-7-methyl-5-azaspiro(2.4)heptan-5-yl)-6-fluoro-1-(2-fluoro-1-cyclopropyl)-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 100%
  • Fluoroquinolones 50%
  • Tuberculosis 37%
  • Moxifloxacin 29%
  • Drug Combinations 11%
  31 Scopus citations

• BCG-mediated protection against Mycobacterium ulcerans infection in the mouse

  Converse, P. J., Almeida, D. V., Nuermberger, E. L. & Grosset, J. H., Mar 2011, In: PLoS neglected tropical diseases. 5, 3, e985.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Buruli Ulcer 100%
  • Mycobacterium ulcerans 85%
  • vaccination 70%
  • Inbred C57BL Mouse 49%
  • Vaccination 33%
  35 Scopus citations

• Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections

  Ahmad, Z., Fraig, M. M., Bisson, G. P., Nuermberger, E. L., Grosset, J. H. & Karakousis, P. C., Apr 2011, In: Antimicrobial agents and chemotherapy. 55, 4, p. 1527-1532 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Pyrazinamide 100%
  • Tuberculosis 61%
  • Animal Models 53%
  • Infections 35%
  • Guinea Pigs 32%
  50 Scopus citations

• Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models

  Ahmad, Z., Fraig, M. M., Pinn, M. L., Tyagi, S., Nuermberger, E. L., Grosset, J. H. & Karakousis, P. C., Jul 2011, In: Journal of Antimicrobial Chemotherapy. 66, 7, p. 1560-1566 7 p., dkr188.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Guinea Pigs 100%
  • Tuberculosis 93%
  • Animal Models 82%
  • Granuloma 77%
  • Drug Therapy 66%
  16 Scopus citations

• Harnessing the full sterilising activity of rifamycins

  Leung, C. C., Yew, W. W. & Grosset, J., Apr 2011, In: International Journal of Tuberculosis and Lung Disease. 15, 4, p. 429-430 2 p.

  Research output: Contribution to journal › Editorial › peer-review
  2 Scopus citations

• History of drug discovery: Early evaluation studies and lessons learnt from them

  Ahmad, Z., Makaya, N. H. & Grosset, J., Sep 2011, Antituberculosis Chemotherapy. Donald, P. & Helden, P. (eds.). p. 2-9 8 p. (Progress in Respiratory Research; vol. 40).

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Drug Discovery 100%
  • Evaluation Studies 87%
  • Pyrazinamide 52%
  • Streptomycin 45%
  • Isoniazid 44%
  5 Scopus citations

• New drugs for tuberculosis treatment

  Sánchez, F., López Colomés, J. L., Villarino, E. & Grosset, J., Mar 2011, In: Enfermedades Infecciosas y Microbiologia Clinica. 29, SUPPL. 1, p. 47-56 10 p.

  Research output: Contribution to journal › Article › peer-review

  • pretomanid 100%
  • Rifampin 87%
  • Moxifloxacin 72%
  • Tuberculosis 68%
  • Rifamycins 47%
  6 Scopus citations